MX2010012037A - Composiciones y uso utiles para tratar trastornos cognitivos. - Google Patents

Composiciones y uso utiles para tratar trastornos cognitivos.

Info

Publication number
MX2010012037A
MX2010012037A MX2010012037A MX2010012037A MX2010012037A MX 2010012037 A MX2010012037 A MX 2010012037A MX 2010012037 A MX2010012037 A MX 2010012037A MX 2010012037 A MX2010012037 A MX 2010012037A MX 2010012037 A MX2010012037 A MX 2010012037A
Authority
MX
Mexico
Prior art keywords
disorder
compound
composition according
cognitive
phenylindan
Prior art date
Application number
MX2010012037A
Other languages
English (en)
Spanish (es)
Inventor
Rene Holm
Christine Kau
Birgitte Willumsen
Klaus Peter Hertel
Karina Kroejer Soeby
Christina Kurre Olsen
Lone Bruun
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of MX2010012037A publication Critical patent/MX2010012037A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
MX2010012037A 2008-05-07 2009-05-07 Composiciones y uso utiles para tratar trastornos cognitivos. MX2010012037A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA200800647 2008-05-07
DKPA200801392 2008-10-03
DKPA200801519 2008-11-04
PCT/DK2009/050107 WO2009135495A1 (en) 2008-05-07 2009-05-07 Method for treating cognitive deficits

Publications (1)

Publication Number Publication Date
MX2010012037A true MX2010012037A (es) 2010-11-30

Family

ID=40870955

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010012037A MX2010012037A (es) 2008-05-07 2009-05-07 Composiciones y uso utiles para tratar trastornos cognitivos.

Country Status (15)

Country Link
US (2) US20090306092A1 (enExample)
EP (1) EP2285377A1 (enExample)
JP (1) JP2011519873A (enExample)
KR (1) KR20110021754A (enExample)
CN (1) CN102065861B (enExample)
AU (1) AU2009243813B2 (enExample)
BR (1) BRPI0912223A2 (enExample)
CA (1) CA2722374A1 (enExample)
CO (1) CO6311083A2 (enExample)
EA (1) EA018927B1 (enExample)
IL (1) IL209084A0 (enExample)
MX (1) MX2010012037A (enExample)
NZ (1) NZ589571A (enExample)
WO (1) WO2009135495A1 (enExample)
ZA (1) ZA201007912B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0919165A2 (pt) * 2008-10-03 2015-12-08 Lundbeck & Co As H composição farmacêutica,e, uso de um composto
TWI552751B (zh) * 2011-06-20 2016-10-11 Ｈ 朗德貝克公司 投予４－（（１ｒ，３ｓ）－６－氯－３－苯基－二氫茚－１－基）－１，２，２－三甲基－哌及其鹽用於治療精神分裂症的方法
PL3135656T3 (pl) 2011-06-20 2019-07-31 H. Lundbeck A/S Deuterowane 1-piperazyno-3-fenyloindany do leczenia schizofrenii
US9265458B2 (en) 2012-12-04 2016-02-23 Sync-Think, Inc. Application of smooth pursuit cognitive testing paradigms to clinical drug development
US9380976B2 (en) 2013-03-11 2016-07-05 Sync-Think, Inc. Optical neuroinformatics
US20210395208A1 (en) * 2018-10-29 2021-12-23 H. Lundeck A/S Amorphous compounds of formula (i) and amorphous compounds of formula (i) salts
EP3891134A1 (en) 2018-12-03 2021-10-13 H. Lundbeck A/S Prodrugs of 4-((1r,3s)-6-chloro-3-phenyl-2,3-dihydro-1h-inden-1-yl)-1,2,2-trimethylpiperazine and 4-((1/r,3s)-6-chloro-3-(phenyl-d5)-2,3-dihydro-1h-inden-1-yl)-2,2-dimethy-1-(methyl-d3)piperazine

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4031216A (en) * 1974-08-12 1977-06-21 Knoll A.G. Chemische Fabriken 3-(3,4-Dialkoxy-benzyl)-3-methyl-piperazines
IE50867B1 (en) * 1980-02-29 1986-08-06 Kefalas As Indane derivatives
DE3139970A1 (de) * 1981-10-08 1983-04-28 Boehringer Mannheim Gmbh, 6800 Mannheim Neue carbonsaeurederivate, verfahren zu ihrer herstellung sowie diese verbindungen enthaltende arzneimittel
US5026853A (en) * 1987-04-01 1991-06-25 Janssen Pharmaceutica N.V. 4-substituted-2(or 3)aminocarbonyl-1-piperazineacetamide
US5466806A (en) * 1989-02-08 1995-11-14 Biochem Pharma Inc. Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
CA2091204C (en) * 1992-03-11 1997-04-08 Ronald J. Mattson Antiischemic-piperazinyl and piperidinyl-cyclohexanes
DK55192D0 (da) * 1992-04-28 1992-04-28 Lundbeck & Co As H 1-piperazino-1,2-dihydroindenderivater
CA2132411A1 (en) * 1994-09-19 1996-03-20 Michael Trani Enzymatic esterification of long-chain racemic acids and alcohols
US6410794B1 (en) * 1994-12-16 2002-06-25 Uop Llc Process for preparation of pharmaceutically desired chiral tetralone from tetralones
US6455736B1 (en) * 1994-12-16 2002-09-24 Uop Llc Process for preparation of pharmaceutically desired sertraline and sertraline analogs
US5807897A (en) * 1996-03-01 1998-09-15 Zeneca Limited Aminotetralin derivative and compositions and method of use thereof
ATE255555T1 (de) * 1998-05-01 2003-12-15 Pfizer Prod Inc Verfahren zur herstellung von enantiomeren reinem oder optisch angereicherter sertraline-tetralon durch kontinuierliche chromatographie
DE19824470A1 (de) * 1998-05-30 1999-12-02 Boehringer Ingelheim Pharma Neue Neurokininantagonisten, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
FR2786769B1 (fr) * 1998-12-04 2002-10-25 Synthelabo Derives de 2,5-diazabicyclo[2.2.1]heptane, leur preparation et leur application en therapeutique
IN187170B (enExample) * 2000-01-04 2002-02-23 Sun Pharmaceutical Ind Ltd
US7396542B2 (en) * 2001-12-28 2008-07-08 Teva Pharmaceutical Industries Ltd. Stable pharmaceutical formulation of paroxetine hydrochloride anhydrous and a process for preparation thereof
AU2003284899A1 (en) * 2002-10-29 2004-05-25 Miicro, Inc. Novel combination therapy for schizophrenia focused on improved cognition: 5-ht-2a/d2 blockade with adjunctive blockade of prefrontal da reuptake
PL1658277T3 (pl) * 2003-08-18 2012-10-31 H Lundbeck As Sól bursztynianowa i malonianowa trans-4-((1R,3S)-6-chloro-3-fenyloindan-1-ylo)-1,2,2-tri-metylopiperazyny i zastosowanie jako lek
TWI376373B (en) * 2005-02-16 2012-11-11 Lundbeck & Co As H Crystalline base of a pharmaceutical compound
TW200640891A (en) * 2005-02-16 2006-12-01 Lundbeck & Co As H Tartrate and malate salts of a pharmarceutical compound
JP2008530039A (ja) * 2005-02-16 2008-08-07 ハー・ルンドベック・アクチエゼルスカベット トランス−１−（（１ｒ，３ｓ）−６−クロロ−３−フェニルインダン−１−イル）−３，３−ジメチルピペラジンの酒石酸塩およびリンゴ酸塩
TW200817400A (en) * 2006-05-30 2008-04-16 Elbion Ag Pyrido [3,2-e] pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them
BRPI0919165A2 (pt) * 2008-10-03 2015-12-08 Lundbeck & Co As H composição farmacêutica,e, uso de um composto

Also Published As

Publication number Publication date
JP2011519873A (ja) 2011-07-14
EA201071273A1 (ru) 2011-06-30
ZA201007912B (en) 2012-02-29
WO2009135495A1 (en) 2009-11-12
HK1157674A1 (en) 2012-07-06
US20090306092A1 (en) 2009-12-10
CN102065861A (zh) 2011-05-18
US20110207744A1 (en) 2011-08-25
AU2009243813B2 (en) 2014-05-29
CA2722374A1 (en) 2009-11-12
CN102065861B (zh) 2013-10-16
EA018927B1 (ru) 2013-11-29
AU2009243813A1 (en) 2009-11-12
NZ589571A (en) 2012-07-27
IL209084A0 (en) 2011-01-31
KR20110021754A (ko) 2011-03-04
EP2285377A1 (en) 2011-02-23
CO6311083A2 (es) 2011-08-22
BRPI0912223A2 (pt) 2015-10-06

Similar Documents

Publication Publication Date Title
Costall et al. Anxiolytic potential of 5‐HT3 receptor antagonists
AU2009243813B2 (en) Method for treating cognitive deficits
Miyamoto et al. Antipsychotic drugs
Meneses et al. 5-HT1AReceptors Modulate the Consolidation of Learning in Normal and Cognitively Impaired Rats
JP6479766B2 (ja) 不安障害患者の治療のためのナルメフェン
KR20110081176A (ko) 경구용 제형물
Costa-Campos et al. Anxiolytic properties of the antipsychotic alkaloid alstonine
US20250319095A1 (en) Use of benzodiazepines to increase sensitivity to psilocybin following a chronic ssri regimen
Takahashi et al. Pharmacological profile of MS-377, a novel antipsychotic agent with selective affinity for σ receptors
Tachere et al. Beyond anxiety and agitation: A clinical approach to akathisia
TW200946142A (en) Tablet
Shao et al. Galanthamine, an acetylcholine inhibitor, prevents prepulse inhibition deficits induced by adolescent social isolation or MK-801 treatment
WO2012163365A1 (en) Combinations of serotonin receptor agonists for treatment of movement disorders
Millan et al. S-16924 [(R)-2-{1-[2-(2, 3-Dihydro-benzo [1, 4] dioxin-5-yloxy)-ethyl]-pyrrolidin-3yl}-1-(4-fluorophenyl)-ethanone], a Novel, Potential Antipsychotic with Marked Serotonin1AAgonist Properties: III. Anxiolytic Actions in Comparison with Clozapine and Haloperidol
Jerlhag The antipsychotic aripiprazole antagonizes the ethanol-and amphetamine-induced locomotor stimulation in mice
Soleimani et al. Research Paper Probiotic Add-on Therapy in the First-Episode Schizophrenia: A Randomized Controlled Trial
Yamamoto et al. Ondansetron, dexamethasone and an NK1 antagonist block radiation sickness in mice
Maguire Impact of antipsychotics on geriatric patients: efficacy, dosing, and compliance
Kitaichi et al. Involvement of the serotonergic neuronal system in phencyclidine-induced place aversion in rats
HK1157674B (en) Use of trans-4((1r,3s)-6-chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine for improving cognition
Svensson et al. Atypical antipsychotic-like effect of AMPA receptor antagonists in the rat
Sachdev et al. Effects of specific dopamine D1 and D2 receptor antagonists and agonists and neuroleptic drugs on emotional defecation in a rat model of akathisia
Burroughs Assessment of Dopaminergic and Serotonergic Receptor Antagonists in Male Rats Trained to Discriminate 4-Methylmethcathinone (Mephedrone)
Rappard et al. P. 3. c. 056 Efficacy of ziprasidone in the treatment of schizoaffective disorder: an analysis of 2 fixed-dose, placebo-controlled trials
Julia Cain et al. Symptom Control in Stem Cell Transplantation: A Multidisciplinary Palliative Care Team Approach

Legal Events

Date Code Title Description
FA Abandonment or withdrawal